CHEMRNA
LIVE

Serial Number

98960020

Owner

Convergence Bio, Inc.

Attorney

Aaron D. Hendelman

Filing Date

Jan 14, 2025

Add to watchlist:

No watchlists yet
View on USPTO

CHEMRNA Trademark

Serial Number: 98960020

CHEMRNA is a trademark filed by Convergence Bio, Inc. on January 14, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Convergence Bio, Inc. (2 trademarks)

800 Boylston St, Ste 2222
Boston, MA 02199

Entity Type: 03

Trademark Details

Filing Date

January 14, 2025

Registration Date

Not Registered

Published for Opposition

April 28, 2026

Goods & Services

Assays and reagents for use in scientific and biomedical research

pharmaceutical preparations, vaccines and medical therapeutics for the prevention and treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations, vaccines and medical therapeutics for improving the aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; vaccines for human use; nutritional and dietary supplements for improving the aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; pharmaceutical preparations, vaccines and medical therapeutics for the prevention and treatment of blood disorders, bone disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes

research and development of therapeutic antibodies and pharmaceuticals, and research and development of technology in the field of therapeutic antibodies, pharmaceuticals and biopharmaceuticals; development of pharmaceutical preparations, vaccines and medicines; clinical studies; drug development and discovery; medical research for development of therapeutic modalities for treatment of diseases; research and development of pharmaceutical preparations, vaccines and therapeutic drugs for the prevention and treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; research and development of therapeutic modalities for treatment of aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; preclinical and clinical development of therapeutic products

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 23, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 28, 2026 NPUB
PUBLISHED FOR OPPOSITION
Apr 28, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 22, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 31, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 31, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 31, 2026 CRFA
ASSIGNED TO LIE
Mar 31, 2026 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Mar 27, 2026 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 30, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 30, 2025 GNSL
SUSPENSION LETTER WRITTEN
Oct 30, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 1, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 1, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 1, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 3, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jul 3, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jul 3, 2025 CNRT
ASSIGNED TO EXAMINER
Jun 23, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 12, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Jan 14, 2025 MAFR
NEW APPLICATION ENTERED
Jan 14, 2025 NWAP